| 產(chǎn)品編號 | bsm-44023M |
| 英文名稱 | Influenza A virus Nucleoprotein H1N1 Mouse mAb |
| 中文名稱 | 流感病毒A核蛋白單克隆抗體 |
| 別 名 | Common flu NP; Influenza A virus NP; NP; Nucleocapsid protein; Nucleoprotein; Protein N; Seasonal Influenza A (H1N1) Nucleocapsid Protein. |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Influenza A Nucleoprotein [A/Victoria/4897/2022 (H1N1)] |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 57 kDa |
| 檢測分子量 | |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant Influenza A virus H1N1(A/Victoria/4897/2022)Nucleoprotein |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The nucleoprotein (NP) of Influenza virus encapsulates the negative strand of the viral RNA and is essential for replicative transcription. It may also be involved in other essential functions throughout the virus life cycle. As well as binding ssRNA, NP is able to self associate to form large oligomeric complexes. NP is able to interact with a variety of other macromolecules of both viral and cellular origins. It binds the PB1 and PB2 subunits of the polymerase and the matrix protein M1. "NP has also been shown to interact with at least four cellular polypeptide families: nuclear import receptors of the importin class, filamentous (F) actin, the nuclear export receptor CRM1 and a DEAD box helicase BAT1/UAP56" (Portela et al 2002). |
| 產(chǎn)品圖片 |
20 ng rInfluenza A virus H1N1(A/Victoria/4897/2022)Nucleoprotein-His protein (bs-44023P) per lane probed with Influenza A virus Nucleoprotein H1N1 monoclonal antibody respectively, unconjugated (bsm-44023M) at 1:1000 dilution and 4°C overnight incubation. Followed by corresponding conjugated secondary antibody incubation at r.t. for 60 min.
|
